Dierick Jean-Francois, Halder Marlies, Jungbaeck Carmen, Lorenz Julie, Préaud Jean-Marie, Riou Patrice, Tesolin Lorenzo, Uhlrich Sylvie, Van Molle Wim, Vandeputte Joris
GSK Vaccines, 89 Rue de l'Institut, Rixensart, 1330, Belgium.
Joint Research Centre, European Commission, Via E. Fermi 2749, Ispra (VA), 21027, Italy.
Open Res Eur. 2022 Dec 13;2:116. doi: 10.12688/openreseurope.15077.2. eCollection 2022.
The aim of this letter is to share the discussions and proposals made by the VAC2VAC consortium on how to support the deployment of the "Consistency Approach" for quality control of established vaccines and thus facilitate the substitution of testing. This work answers specific questions about " and " . Some topics were answered in a very straightforward manner. This was the case when the deployment of the consistency approach and the corresponding changes in vaccines control strategy was supported by the generic application of procedures already described in regulatory guidelines/requirements and related to the establishment or change in the control strategy of vaccines. The application of other procedures required more specific attention and some were deeply debated before reaching a proposal. The key outcomes of this work are that robust science must be used to develop a substitution strategy and generate supportive data packages. And this good science can best occur with good scientific collaboration between the different parties involved. Therefore, early interaction between manufacturers and competent authorities before and during dossier submission is critical to success. The consistency approach, when approved and in place, will ensure vaccine products of assured quality reach the patient in a more efficient manner than when relying on testing. Adapting the mindset was one of the major hurdles to a progressive vision but there is now consensus between manufacturers and competent authorities to foster the elimination of testing for routine vaccine release testing.
本信函旨在分享VAC2VAC联盟就如何支持采用“一致性方法”进行已上市疫苗质量控制从而推动替代检测所进行的讨论和提出的建议。这项工作回答了有关“……”和“……”的具体问题。一些主题的答案非常直接。当一致性方法的部署以及疫苗控制策略的相应变化得到监管指南/要求中已描述的、与疫苗控制策略的制定或变更相关的程序的通用应用支持时,情况就是如此。其他程序的应用需要更具体的关注,有些在形成提案之前还进行了深入辩论。这项工作的关键成果是,必须运用可靠的科学来制定替代策略并生成支持性数据包。而且这种良好的科学最好通过相关各方之间良好的科学合作来实现。因此,制造商和主管当局在提交档案之前和期间的早期互动对于成功至关重要。一致性方法一旦获批并实施,将确保质量有保证的疫苗产品比依赖……检测时更高效地送达患者手中。转变观念是实现进步愿景的主要障碍之一,但目前制造商和主管当局已达成共识,要推动消除用于常规疫苗放行检测的……检测。